← 返回

肿瘤免疫治疗与免疫制品应用:文献综述

英文原题:Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.

查看英文原题

Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.

PubMed 2024/10/24(内容时间) J Immunol Res Q3 · IF 3.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

恶性肿瘤以细胞不受控制地增殖为特征,是全球主要的健康挑战之一,2022年导致超过970万例死亡,预计到2050年每年新增病例将升至3500万。免疫治疗优于其他癌症疗法,能够精准靶向恶性细胞,同时增强免疫系统复杂的应答反应。这一新兴科学领域的进展与对肿瘤生物学的深入认识密切相关,尤其是肿瘤细胞、免疫系统与肿瘤微环境(TME)之间复杂的相互作用,这些是癌症进展和免疫逃逸的核心。本综述全面分析了调控这些相互作用的分子机制,强调其在有效免疫治疗产品开发中的关键作用。我们批判性地评估了当前的免疫治疗方法,包括癌症疫苗、过继性T细胞疗法和基于细胞因子的治疗,重点阐述其疗效和安全性。我们还探讨了联合治疗的最新进展,这些策略协同整合多种免疫治疗手段以克服耐药并提高治疗效果。本综述提供了关于癌症免疫治疗未来的关键见解,重点关注推进更有效和个性化的治疗策略。

展开英文摘要原文

Malignant tumors, characterized by uncontrolled cell proliferation, are a leading global health challenge, responsible for over 9. 7 million deaths in 2022, with new cases expected to rise to 35 million annually by 2050. Immunotherapy is preferred to other cancer therapies, offering precise targeting of malignant cells while simultaneously strengthening the immune system's complex responses.

Advances in this novel field of science have been closely linked to a deeper knowledge of tumor biology, particularly the intricate interplay between tumor cells, the immune system, and the tumor microenvironment (TME), which are central to cancer progression and immune evasion. This review offers a comprehensive analysis of the molecular mechanisms that govern these interactions, emphasizing their critical role in the development of effective immunotherapeutic products.

We critically evaluate the current immunotherapy approaches, including cancer vaccines, adoptive T cell therapies, and cytokine-based treatments, highlighting their efficacy and safety.

We also explore the latest advancements in combination therapies, which synergistically integrate multiple immunotherapeutic strategies to overcome resistance and enhance therapeutic outcomes. This review offers key insights into the future of cancer immunotherapy with a focus on advancing more effective and personalized treatment strategies.

论文信息

作者
Oli AN、Adejumo SA、Rowaiye AB、Ogidigo JO、Hampton-Marcell J、Ibeanu GC
第一作者单位
Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka 420211, Nigeria.Nigeria
通讯作者单位
Department of Pharmaceutical Science, North Carolina Central University, Durham 27707, North Carolina, USA.United States
文献类型
综述
期刊
Journal of immunology research2024
原文标识
PubMed 39483536 · DOI 10.1155/2024/8481761